Appeal in writing, inside the plan’s window, against the reason the notice actually gives. Federal rules give members of most group health plans at least 180 days to file internally and an independent external review afterwards. For this drug class the argument that succeeds most often is about indication, not about weight loss in general.
The notice sets the argument, not the other way round
An adverse determination has to state a specific reason and point to the plan provision or criteria relied on. Everything in the appeal should answer that sentence. A submission arguing broadly for obesity treatment against a notice citing an undocumented diagnosis loses on relevance, while a submission attaching the missing record often succeeds without any argument at all.
Members can request, free of charge, the documents relevant to the claim, including the internal criteria applied. Since each Blue Cross licensee is a separate company with its own policies, and a self-funded employer can direct its own variations, that request is the only reliable way to learn which rules were used.
Indication is the argument that moves decisions
Semaglutide and tirzepatide are each sold as two branded products with different approved uses. Ozempic covers glycemic control in type 2 diabetes plus cardiovascular and kidney outcomes; Wegovy covers long-term weight reduction, cardiovascular risk reduction in adults with established disease and excess weight, and noncirrhotic metabolic dysfunction-associated steatohepatitis. Mounjaro covers type 2 diabetes; Zepbound covers weight reduction and moderate to severe obstructive sleep apnea in adults with obesity.
That structure creates real openings. A member refused a weight-management product may have a documented cardiovascular history, liver disease or sleep apnea that puts the request inside a different approval on the same label. The sleep apnea route in particular is supported by a randomized trial in adults with obesity and is frequently overlooked, because most people frame the request as a weight request from the start.
Working out which approval applies is easier with a plain breakdown in hand, and providers publish these unevenly. Ro and Henry Meds lean on their own intake flows, while HealthRX keeps a page on GLP-1 insurance coverage that separates the diabetes and weight approvals product by product. A member can use that to frame the appeal around the indication the plan is set up to recognize rather than a general case for treatment.
Match the tool to the refusal
| Reason on the notice | Better tool | Where it goes next |
|---|---|---|
| Documentation incomplete | Internal appeal with records attached | External review if refused again |
| Product not on the drug list | Formulary exception request | Appeal of the exception decision |
| Indication not supported | Corrected clinical record, new request | Internal appeal if still refused |
| Criteria not met on clinical grounds | Internal appeal, prescriber letter | Independent external review |
| Category excluded by the employer | Employer benefits team | Rarely reviewable externally |
| Medicare drug plan refusal | Coverage determination, then redetermination | Independent review entity, then further stages |
An exception request is not an appeal
These get confused constantly and the confusion costs weeks. An exception asks the plan to cover something outside its list or to waive a restriction, and it is decided through the coverage determination process. An appeal challenges a decision that has already been issued. Filing an appeal when the situation calls for an exception produces a procedurally correct refusal that answers nothing.
The internal stage is where most reversals happen
Reviews at this stage must be conducted by someone uninvolved in the original decision, and where medical judgment was involved, an appropriate clinical professional has to be consulted. Strong submissions are short and structured: the criterion cited, the evidence meeting it, dated records attached. A prescriber letter that recites clinical history with dates outperforms one describing how much the treatment is wanted.
Timing rules are published. Internal decisions on care not yet received arrive faster than decisions on care already given, and urgent requests move to a much shorter clock. Filing in writing fixes the date, which matters when the next stage is measured in months.
External review takes the decision out of the building
After a final internal refusal, non-grandfathered plans must offer an independent external review at no cost, decided by an organization with no financial relationship to the plan, and the outcome binds the plan. Most people never reach this stage because they read the second refusal as the end. External review generally covers decisions involving medical judgment, which is why a straightforward benefit exclusion rarely qualifies.
Medicare runs a separate ladder
Part D starts with a coverage determination, then redetermination by the plan, then reconsideration by an independent entity under contract to CMS, then a hearing, then the Appeals Council, then federal court. Each rung has its own filing window and the later ones carry a minimum amount in dispute. Drugs used for weight loss have historically sat outside the Part D benefit, so the live question is often whether a different medically accepted indication applies.
Do not stop treatment while the clock runs
Appeals take weeks even when they work, and the published maintenance data show weight regain after these drugs are withdrawn, so an interruption is not a neutral pause. Running a parallel cash track is a hedge rather than a concession, and manufacturer channels publish figures for the branded products.
On the compounded side, supervised practices including Ro, Hims and Hers and FormBlends list monthly cash prices for semaglutide and tirzepatide prescribed after a clinician review. Compounded medication is not FDA-approved and is not evaluated by the agency for safety, effectiveness or manufacturing quality, which is a reason to keep a prescriber involved rather than treat it as a retail purchase.
Frequently asked questions
Who can file on the member’s behalf?
An authorized representative, most often the prescribing clinician or a family member, once the plan’s form is on file. For urgent requests a treating provider can generally act as representative before the paperwork completes, which saves days at the stage where days matter most.
Does citing the clinical trials help?
Only a little. Trial evidence establishes that the drug class works, which is rarely in dispute. Reviewers decide against plan criteria, so the useful citations are the ones showing this patient meets this criterion. Published treatment guidelines carry more weight than efficacy data alone.
How often do appeals succeed?
Rates differ sharply by plan type and refusal reason, and no single number describes them. The consistent pattern is that reversals cluster where the original refusal was documentation-driven and new records were supplied, and are uncommon where the plan sponsor excluded the benefit category outright.
What happens after an external reviewer sides with the member?
The determination binds the plan, which must provide coverage consistent with it. Implementation is not always immediate, so confirming with the pharmacy that the authorization has posted before attempting a fill avoids a second rejection at the counter over an administrative lag
